SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?


To: Bryan Arnold who wrote (4017)4/10/1998 9:47:00 AM
From: Easy Mark  Read Replies (1) | Respond to of 6136
 
Isn't the basic problem with AGPH that there are too many competing drugs in the pipeline. The key competitive issues for anti-viral drugs are their side effects and treatment regime. We saw with the results of Preveon announced, that several drugs are moving to market that have better quality of life features, while still providing effective anti-viral activity.